Compare Fresenius Kabi Onco. with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SUN PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SUN PHARMA FRESENIUS KABI ONCO./
SUN PHARMA
 
P/E (TTM) x 22.1 77.2 28.7% View Chart
P/BV x 3.1 3.3 94.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FRESENIUS KABI ONCO.   SUN PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SUN PHARMA
Mar-20
FRESENIUS KABI ONCO./
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs176484 36.4%   
Low Rs79315 24.9%   
Sales per share (Unadj.) Rs37.7136.9 27.5%  
Earnings per share (Unadj.) Rs5.117.5 29.2%  
Cash flow per share (Unadj.) Rs6.726.0 25.9%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs42.5188.7 22.6%  
Shares outstanding (eoy) m158.232,399.26 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.9 115.6%   
Avg P/E ratio x25.022.9 109.1%  
P/CF ratio (eoy) x18.915.4 123.2%  
Price / Book Value ratio x3.02.1 141.2%  
Dividend payout %022.9 0.0%   
Avg Mkt Cap Rs m20,135958,864 2.1%   
No. of employees `0001.217.8 6.5%   
Total wages/salary Rs m70363,624 1.1%   
Avg. sales/employee Rs Th5,176.218,490.6 28.0%   
Avg. wages/employee Rs Th610.43,582.6 17.0%   
Avg. net profit/employee Rs Th699.62,357.6 29.7%   
INCOME DATA
Net Sales Rs m5,963328,375 1.8%  
Other income Rs m186,360 0.3%   
Total revenues Rs m5,981334,735 1.8%   
Gross profit Rs m1,43069,898 2.0%  
Depreciation Rs m25820,528 1.3%   
Interest Rs m-263,027 -0.9%   
Profit before tax Rs m1,21652,702 2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-2,606 2.6%   
Tax Rs m3428,228 4.2%   
Profit after tax Rs m80641,868 1.9%  
Gross profit margin %24.021.3 112.7%  
Effective tax rate %28.115.6 180.2%   
Net profit margin %13.512.8 106.0%  
BALANCE SHEET DATA
Current assets Rs m5,102316,542 1.6%   
Current liabilities Rs m2,385157,064 1.5%   
Net working cap to sales %45.648.6 93.8%  
Current ratio x2.12.0 106.1%  
Inventory Days Days15088 171.4%  
Debtors Days Days113105 108.2%  
Net fixed assets Rs m5,148243,102 2.1%   
Share capital Rs m1582,399 6.6%   
"Free" reserves Rs m6,556450,245 1.5%   
Net worth Rs m6,732452,645 1.5%   
Long term debt Rs m95220,289 4.7%   
Total assets Rs m10,388682,525 1.5%  
Interest coverage x-45.818.4 -248.7%   
Debt to equity ratio x0.10 315.6%  
Sales to assets ratio x0.60.5 119.3%   
Return on assets %7.56.6 114.1%  
Return on equity %12.09.2 129.4%  
Return on capital %14.611.2 130.0%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29874,219 7.1%   
Fx outflow Rs m1,77227,964 6.3%   
Net fx Rs m3,52546,255 7.6%   
CASH FLOW
From Operations Rs m1,27465,548 1.9%  
From Investments Rs m-1,204-25,888 4.7%  
From Financial Activity Rs m-196-57,151 0.3%  
Net Cashflow Rs m-126-13,857 0.9%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.1 5.8%  
FIIs % 9.6 23.0 41.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.3 109.6%  
Shareholders   42,599 133,026 32.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFE SCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 1,708 Points Today(Closing)

Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - PIRAMAL ENTERPRISES COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS